Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Common Equity (2022 - 2025)

Historic Common Equity for Gossamer Bio (GOSS) over the last 4 years, with Q3 2025 value amounting to -$82.3 million.

  • Gossamer Bio's Common Equity fell 25208.55% to -$82.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$82.3 million, marking a year-over-year decrease of 25208.55%. This contributed to the annual value of $29.5 million for FY2024, which is 5301.5% down from last year.
  • Gossamer Bio's Common Equity amounted to -$82.3 million in Q3 2025, which was down 25208.55% from -$46.1 million recorded in Q2 2025.
  • In the past 5 years, Gossamer Bio's Common Equity ranged from a high of $104.6 million in Q3 2023 and a low of -$82.3 million during Q3 2025
  • In the last 4 years, Gossamer Bio's Common Equity had a median value of $26.7 million in 2024 and averaged $14.4 million.
  • Data for Gossamer Bio's Common Equity shows a peak YoY increase of 41974.0% (in 2023) and a maximum YoY decrease of 28150.78% (in 2023) over the last 5 years.
  • Over the past 4 years, Gossamer Bio's Common Equity (Quarter) stood at $12.1 million in 2022, then surged by 419.74% to $62.8 million in 2023, then tumbled by 53.02% to $29.5 million in 2024, then plummeted by 379.17% to -$82.3 million in 2025.
  • Its Common Equity was -$82.3 million in Q3 2025, compared to -$46.1 million in Q2 2025 and -$6.2 million in Q1 2025.